



IGM Biosciences to Present at Two Upcoming Investor Conferences

November 7, 2023

MOUNTAIN VIEW, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at two upcoming investor conferences:

- Stifel Healthcare Conference on Tuesday, November 14 at 2:25 p.m. EST in New York
- Jefferies London Healthcare Conference on Thursday, November 16 at 9:00 a.m. GMT/ 4:00 a.m. EST in London

A live webcast of the events will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at <https://investor.igmbio.com/news-and-events/events-and-presentations>. A replay of the webcasts will be archived on the Company's website for 90 days following the presentations.

About IGM Biosciences, Inc.

IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, autoimmune and inflammatory diseases and infectious diseases. IGM's pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and immunology and inflammation targets. For more information, please visit www.igmbio.com.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com



Source: IGM Biosciences, Inc.